Copyright Reports & Markets. All rights reserved.

Global and China Postmenopausal Vaginal Atrophy Treatment Market Research by Company, Type & Application 2013-2025

Buy now

Table of Content

    1 Market Overview

    • 1.1 Market Segment Overview
      • 1.1.1 Product Definition
      • 1.1.2 Market by Type
        • 1.1.2.1 Creams
        • 1.1.2.2 Tablets
        • 1.1.2.3 Patches
        • 1.1.2.4 Rings
      • 1.1.3 Market by Application
        • 1.1.3.1 Topical Estrogen
        • 1.1.3.2 Systemic Estrogen
        • 1.1.3.3 Non-hormonal Therapy
    • 1.2 Global and China Market Size
      • 1.2.1 Global Overview
      • 1.2.2 China Overview

    2 Global and China Market by Company

    • 2.1 Global
      • 2.1.1 Global Sales by Company
      • 2.1.2 Global Price by Company
    • 2.2 China
      • 2.2.1 China Sales by Company
      • 2.2.2 China Price by Company

    3 Global and China Market by Type

    • 3.1 Global
      • 3.1.1 Global Sales by Type
      • 3.1.2 Global Price by Type
    • 3.2 China
      • 3.2.1 China Sales by Type
      • 3.2.2 China Price by Type

    4 Global and China Market by Application

    • 4.1 Global
      • 4.1.1 Global Sales by Application
      • 4.1.2 Global Price by Application
    • 4.2 China
      • 4.2.1 China Sales by Application
      • 4.2.2 China Price by Application

    5 China Trade

    • 5.1 Export
    • 5.2 Import

    6 Key Manufacturers

    • 6.1 Allergan
      • 6.1.1 Company Information
      • 6.1.2 Product Specifications
      • 6.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
    • 6.2 Pfizer
    • 6.3 Shionogi
    • 6.4 Novo Nordisk
    • 6.5 Teva Pharmaceutical
    • 6.6 Bayer.

    7 Industry Upstream

    • 7.1 Industry Chain
    • 7.2 Raw Materials

    8 Market Environment

    • 8.1 SWOT
    • 8.2 Porter's Five Forces

    9 Conclusion

    Summary
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.
    Market Segment as follows:
    By Type
    Creams
    Tablets
    Patches
    Rings
    By Application
    Topical Estrogen
    Systemic Estrogen
    Non-hormonal Therapy
    By Company
    Allergan
    Pfizer
    Shionogi
    Novo Nordisk
    Teva Pharmaceutical
    Bayer.
    The main contents of the report including:
    Section 1:
    Product definition, type and application, global and China market overview;
    Section 2:
    Global and China Market competition by company;
    Section 3:
    Global and China sales revenue, volume and price by type;
    Section 4:
    Global and China sales revenue, volume and price by application;
    Section 5:
    China export and import;
    Section 6:
    Company information, business overview, sales data and product specifications;
    Section 7:
    Industry chain and raw materials;
    Section 8:
    SWOT and Porter's Five Forces;
    Section 9:
    Conclusion.

    Buy now